Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

REC 0/0559 øjendråber til behandling af moderat og svær neurotrofisk keratitis hos voksne patienter

14. september 2026 opdateret af: RECORDATI GROUP

Effekt, sikkerhed og farmakokinetik af 3 doser REC 0/0559 øjendråber til behandling af trin 2 (moderat) og 3 (alvorlig) neurotrofisk keratitis hos voksne patienter

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

108

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Glasgow, Det Forenede Kongerige, G75 8RG
        • University Hospital Hairmyres
      • London, Det Forenede Kongerige
        • Moorfields Eye Hospital NHS Foundation Trust
      • Southampton, Det Forenede Kongerige, SO16 6YD
        • Southampton General Hospital
    • Mersey
      • Liverpool, Mersey, Det Forenede Kongerige, L7 8XP
        • Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre
    • Florida
      • Crystal River, Florida, Forenede Stater, 34429-8722
        • Nature Coast Clinical Research
      • Gainesville, Florida, Forenede Stater, 32605
        • University of Florida
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • University of Maryland School of Medicine UMSOM
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48105
        • University of Michigan - Kellogg Eye Center
    • New York
      • New York, New York, Forenede Stater, 10003
        • Mt. Sinai New York Eye and Ear Infirmary
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Wake Forest Baptist Medical Center
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37215
        • Toyos Clinic
    • Texas
      • Houston, Texas, Forenede Stater, 77025
        • Houston Eye Associates HEA - Gramercy Location
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53705
        • University of Wisconsin-Madison
      • Dijon, Frankrig, 21000
        • Dijon University Hospital CHU Dijon
      • Paris, Frankrig
        • Hôpital Fondation Adolphe de Rothschild
      • Paris, Frankrig, 75014
        • CHU Paris Centre - Hôpital Cochin
      • Paris, Frankrig
        • Hôpital Universitaire Necker
      • Bari, Italien, 70124
        • Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
      • Bologna, Italien, 40138
        • DIMES Universit di Bologna
      • Florence, Italien, 50134
        • Azienda Ospedaliero-Universitaria Careggi
      • Forlì, Italien
        • Ospedali Privato
      • Genova, Italien, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Messina, Italien
        • Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
      • Milan, Italien, 20157
        • Ospedale Luigi Sacco
      • Roma, Italien, 00133
        • Fondazione PTV - Policlinico Tor Vergata
    • Calabria
      • Germaneto, Calabria, Italien, 88100
        • Università Magna Grecia di Catanzaro
      • Barakaldo, Spanien, 48903
        • Hospital de Cruces
      • Barcelona, Spanien
        • Centro de Oftalmologia Barraquer
      • Barcelona, Spanien, 08035
        • Instituto Microcirugia Ocular IMO
      • Madrid, Spanien, 28040
        • Hospital Clinico San Carlos
      • Seville, Spanien
        • Cartuja Vision - Centro de Servicios Oftlamologicos
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33012
        • Instituto Oftalmologico Fernandez-Vega
      • Cologne, Tyskland, 50924
        • Uniklinik Koeln
      • Düsseldorf, Tyskland, 40225
        • Hospital Eye University of Duesseldorf
      • Frankfurt, Tyskland, 60590
        • Universitaetsklinikum Frankfurt
      • Homburg, Tyskland
        • Saarland University Medical Center
      • Mainz, Tyskland, 55131
        • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    • Bavaria
      • Munich, Bavaria, Tyskland, 80336
        • Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
      • Budapest, Ungarn
        • Semmelweis University, Dept. of Ophthalmology
      • Pécs, Ungarn
        • University of Pecs - Dpt of Ophthalmology
    • Vas County
      • Szombathely, Vas County, Ungarn, 9700
        • Markusovszky University Teaching Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Have read, understood, and signed the informed consent form (ICF).

  2. Be a male or female aged ≥18 years at the time of ICF signature.

  3. Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.

    for the study eye

  4. Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.

  5. Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.

  6. Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.

Exclusion Criteria:

  1. Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.

  2. Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8

  3. Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.

  4. Have a significant history of alcohol abuse or drug/solvent abuse

  5. Be unwilling to comply with any study assessments or procedures.

  6. Be a woman who is pregnant, nursing or planning a pregnancy.

  7. Be a woman of childbearing potential not using a highly effective method of birth control.

  8. Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.

    For the study eye:

  9. Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.

  10. Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),

  11. Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).

  12. Have severe blepharitis and/or severe meibomian gland disease in the study eye.

  13. Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.

  14. Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.

  15. Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.

  16. Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.

  17. Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.

  18. Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.

  19. Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.

  20. Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.

    For the fellow eye

  21. Have Stage 2 or 3 NK or perforation.

    For any eye:

  22. Have a history of ocular cancer.

  23. Have had prior treatment with Oxervate™

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose 1 - 0.5 µg/day

Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Andre navne:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Eksperimentel: Dose 2 - 2.5 µg/day

Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Andre navne:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Eksperimentel: Dose 3 - 5 µg/day

Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Andre navne:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Placebo komparator: Vehicle

Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID

Eye drop solution with no active substance in single dose unit.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Corneal Healing
Tidsramme: At week 8

The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.

At week 8

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Visual Acuity
Tidsramme: At week 8

Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively).

At week 8

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. oktober 2020

Primær færdiggørelse (Faktiske)

29. april 2024

Studieafslutning (Faktiske)

29. april 2024

Datoer for studieregistrering

Først indsendt

17. februar 2020

Først indsendt, der opfyldte QC-kriterier

17. februar 2020

Først opslået (Faktiske)

19. februar 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • REC0559-B-001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner